Skip to content
preclinicalCognitive & Anxiety

Neurotensin

Also known as: NT, Neurotensin 1-13, NTS

Neurotensin is a 13-amino-acid neuropeptide found in the brain and gastrointestinal tract that modulates dopamine neurotransmission, pain perception, body temperature, and fat metabolism. It acts through three receptor subtypes (NTS1, NTS2, NTS3/sortilin), with NTS1 mediating most of its central effects. Neurotensin is co-released with dopamine in mesolimbic pathways and functions as an endogenous neuroleptic — it produces antipsychotic-like effects and hypothermia. NTS1 agonists are being developed as novel non-dopaminergic antipsychotics and analgesics.

4 cited references·5 researched benefits

Quick Answer

Neurotensin is a 13-amino-acid gut-brain peptide that modulates dopamine transmission, pain, thermoregulation, and fat absorption. In the brain, it functions as an endogenous neuroleptic — activating NTS1 receptors produces antipsychotic-like effects without the motor side effects of dopamine blockers. In the gut, it facilitates fat absorption and mediates gut-brain communication. NTS1 agonists are in development as novel antipsychotics and analgesics with potentially fewer side effects than current treatments.

Key Facts

Mechanism
Neurotensin (pGlu-Leu-Tyr-Glu-Asn-Lys-Pro-Arg-Arg-Pro-Tyr-Ile-Leu) signals through NTS1 (Gq-coupled, main CNS receptor), NTS2 (Gi-coupled, pain modulation), and NTS3/sortilin (single-pass receptor, intracellular trafficking). In the ventral tegmental area, neurotensin enhances dopamine neuron firing while simultaneously blocking postsynaptic dopamine D2 receptors, producing a net "antipsychotic-like" effect. In pain pathways, NTS2 activation in the spinal cord produces opioid-independent analgesia. Peripherally, neurotensin is the primary mediator of fat-stimulated GI hormone release and lipid absorption.
Research Status
preclinical
Half-Life
~1–3 minutes (rapidly degraded by metalloendopeptidases)
Molecular Formula
C₇₈H₁₂₁N₂₁O₂₀
Primary Use
Cognitive & Anxiety
Table of Contents

Benefits

  • Endogenous antipsychotic — NTS1 activation produces antipsychotic effects without extrapyramidal motor side effects of D2 blockersmoderate
  • Non-opioid analgesia — NTS2 agonists produce significant pain relief through opioid-independent mechanisms, without addiction riskmoderate
  • Hypothermic neuroprotection — neurotensin-induced hypothermia may protect against ischemic brain injurypreliminary
  • Fat metabolism regulation — mediates gut fat absorption and systemic lipid metabolismmoderate
  • Biomarker potential — plasma neurotensin levels predict metabolic syndrome, diabetes, and cardiovascular riskmoderate

Dosage Protocols

RouteDosage RangeFrequencyNotes
Research use onlyN/AN/ANot available therapeutically. NTS1 agonists and NTS2-selective agonists are in preclinical development for schizophrenia and pain, respectively. Brain-penetrant neurotensin analogs with extended half-lives are being engineered to overcome the rapid degradation of native neurotensin.

Medical disclaimer

Dosage information is provided for educational reference only. Always follow your prescriber's instructions and consult a qualified healthcare provider before starting any peptide protocol.

Side Effects

  • Hypothermia — significant body temperature reduction is a hallmark effect of central neurotensin administrationcommon
  • Hypotension — neurotensin causes vasodilation and blood pressure reductioncommon
  • Reduced locomotor activity — sedation and motor suppression through dopaminergic modulationcommon
  • GI effects — peripheral neurotensin alters gut motility and secretioncommon

Frequently Asked Questions

Why is neurotensin called an endogenous neuroleptic?
In 1980, researchers observed that central neurotensin injection produces effects remarkably similar to antipsychotic drugs: reduced locomotion, hypothermia, and catalepsy — but without the extrapyramidal motor side effects of dopamine D2 receptor blockers. Neurotensin achieves this by modulating dopamine circuits differently: it enhances dopamine neuron firing in the VTA (potentially improving negative symptoms) while blocking postsynaptic D2 signaling (reducing positive symptoms). This dual mechanism inspired development of NTS1 agonists as next-generation antipsychotics.
Can neurotensin-based drugs treat pain without opioid addiction risk?
NTS2 receptor agonists produce robust analgesia in preclinical pain models through mechanisms entirely independent of opioid receptors. This means no euphoria, no respiratory depression, no addiction potential, and no cross-tolerance with opioids. The challenge has been developing NTS2 agonists that cross the blood-brain barrier and resist rapid enzymatic degradation. Several academic and pharmaceutical groups are working on stabilized neurotensin analogs and small molecule NTS2 agonists as opioid alternatives for chronic pain.
What is the connection between neurotensin and obesity?
Large epidemiological studies (Malmö Diet and Cancer Study, >4,600 participants) found that high fasting plasma neurotensin levels independently predict future development of obesity, diabetes, metabolic syndrome, and cardiovascular disease. Neurotensin promotes intestinal fat absorption — neurotensin-deficient mice are resistant to high-fat diet-induced obesity. This suggests that blocking peripheral neurotensin signaling could reduce fat absorption and prevent metabolic disease, making NTS1 antagonists potential anti-obesity agents.
How was neurotensin discovered?
Neurotensin was discovered in 1973 by Susan Leeman and Robert Carraway at Harvard Medical School. They isolated it from bovine hypothalamic extracts based on its ability to cause visible vasodilation (flushing) in anesthetized rats — hence the name "neurotensin" (neuro = brain origin, tensin = blood pressure effect). The 13-amino-acid sequence was determined shortly after, and its dual role as both a brain neurotransmitter and gut hormone was recognized as another example of the gut-brain peptide connection.

References

  1. 1
    Neurotensin as an endogenous antipsychotic: review of the evidence(2010)PubMed ↗
  2. 2
    Neurotensin receptor agonists for non-opioid pain management(2018)PubMed ↗
  3. 3
    Proneurotensin and the risk of diabetes, cardiovascular disease, and mortality(2012)PubMed ↗
  4. 4
    Neurotensin: physiological roles and clinical implications(2018)PubMed ↗

Latest Research

Last updated: 2026-02-19